Get the Stockscreener App
1.15
0.44%
0.015
Tiziana Life Sciences Ltd stock is traded at $1.15, with a volume of 1.83M.
It is up +0.44% in the last 24 hours and up +6.54% over the past month.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Non-Active Secondary Progressive Multiple Sclerosis, Multiple System Atrophy, Alzheimer's, and Amyotrophic Lateral Sclerosis. The company's mission is to design and deliver next-generation immunotherapies for neurodegenerative and neuroinflammatory diseases. The company's main immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's, and other CNS indications.
See More
Previous Close:
$1.135
Open:
$1.15
24h Volume:
1.83M
Relative Volume:
4.31
Market Cap:
$146.35M
Revenue:
-
Net Income/Loss:
$-18.43M
P/E Ratio:
-7.3813
EPS:
-0.1558
Net Cash Flow:
$-12.87M
1W Performance:
+12.87%
1M Performance:
+6.54%
6M Performance:
-17.99%
1Y Performance:
-42.13%
1-Day Range:
$1.05
$1.17
1-Week Range:
$0.9395
$1.195
52-Week Range:
$0.8663
$2.35
Tiziana Life Sciences Ltd Stock (TLSA) Company Profile
Name
Tiziana Life Sciences Ltd
Sector
Industry
Phone
-
Address
-
Compare TLSA vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TLSA
Tiziana Life Sciences Ltd
|
1.15 | 144.44M | 0 | -18.43M | -12.87M | -0.1558 |
VRTX
Vertex Pharmaceuticals Inc
|
516.12 | 128.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
806.07 | 82.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
990.31 | 53.26B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
212.08 | 43.66B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
362.55 | 39.31B | 5.76B | 514.49M | 1.10B | 4.4813 |
Tiziana Life Sciences Ltd Stock (TLSA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-22-20 | Initiated | B. Riley Securities | Buy |
| Dec-17-18 | Initiated | Laidlaw | Buy |
Tiziana Life Sciences Ltd Stock (TLSA) Latest News
Tiziana Life Sciences Ltd (TLSA) Earnings Forecast: Future EPS & Revenue Growth Estimates - tradingkey.com
Tiziana Life Sciences (TLSA) insider adds 42,357 shares via Panetta Partners - Stock Titan
Tiziana Life Sciences Ltd (TLSA) director adds 15,000 shares in open-market buy - Stock Titan
Tiziana Life Sciences CEO & Executive Director Acquires 18% More Stock - simplywall.st
Tiziana Life Sciences (TLSA) CEO Boosts Stake Amid Unprofitable Operations and Low Valuation - GuruFocus
TLSA | Tiziana Life Sciences Ltd. Insider Trading - Quiver Quantitative
Insider Buying: Tiziana Life Sciences (NASDAQ:TLSA) CEO Purchases 83,807 Shares of Stock - MarketBeat
Ivor Elrifi Acquires 237,616 Shares of Tiziana Life Sciences (NASDAQ:TLSA) Stock - marketbeat.com
Tiziana Life Sciences : Announces Purchase of Shares by Chief Executive Officer - marketscreener.com
Tiziana Life Sciences (Nasdaq: TLSA) CEO boosts stake with 321,423-share buy - Stock Titan
Tiziana Life Sciences announces CEO share purchase - Proactive financial news
Tiziana Life Sciences (TLSA) CEO buys 321,423 shares via trust - Stock Titan
Tiziana Life Sciences (NASDAQ:TLSA) CEO Ivor Elrifi Purchases 667,000 Shares - MarketBeat
Tiziana Life Sciences (TLSA) CEO buys 667,000 new shares - Stock Titan
Tiziana Life Sciences CEO Boosts Stake as Lead MS Therapy Progresses - The Globe and Mail
Tiziana Life Sciences (TLSA) CEO Boosts Stake Amid Positive MS T - GuruFocus
Tiziana Life Sciences (NASDAQ: TLSA) CEO purchases 667,000 shares at $1 - Stock Titan
Tiziana CEO adds to holdings - Proactive financial news
Tiziana Life Sciences (TLSA) Slips 5.8% to $0.97, Approaches Key Support at $0.92Reversal Setup Alerts - dars.gov.et
Tiziana Life Sciences Ltd Revenue Breakdown – NASDAQ:TLSA - TradingView
Small cap wrap: Medicus Pharma, Tiziana Life Sciences, Namibia Critical Metals... - Proactive financial news
Tiziana Life Sciences Posts Reproducible PET Evidence of Reduced Brain Inflammation in Third MSA Patient - TipRanks
Tiziana Life Sciences Reports Reduced Neuroinflammation in Third Multiple System Atrophy Patient Treated with Intranasal Foralumab - Quiver Quantitative
Reduced brain inflammation seen in MSA trial at Tiziana (Nasdaq: TLSA) - Stock Titan
Tiziana Reports Reduction in Brain Inflammation in Third - GlobeNewswire
Tiziana Reports Reduction in Brain Inflammation in Third Multiple System Atrophy Patient Treated with Intranasal Foralumab - The Manila Times
Tiziana Life Sciences Ltd (TLSA) Institutional Confidence - TradingKey
Tiziana Life Sciences Ltd (TLSA) Cash Flow - TradingKey
Tiziana Life Sciences Ltd (TLSA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Tiziana Life Sciences Ltd (TLSA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
TLSA|Tiziana Life Sciences Ltd|Price:0.985|Chg%:-0.005 - TradingKey
Tiziana Life Sciences Ltd (TLSA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Tiziana Life Sciences Ltd (TLSA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Tiziana Life Sciences Ltd (TLSA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Tiziana Life Sciences Ltd (TLSA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
TLSA|Tiziana Life Sciences Ltd|Price:0.910|Chg%:+0.018 - TradingKey
TradingKey - TradingKey
Tiziana Life Sciences Ltd. Revenue Breakdown – FWB:0RP - TradingView
Tiziana Life Sciences Ltd. Revenue Breakdown – GETTEX:0RP - TradingView
Tiziana Life Sciences (TLSA) insider awarded 42,357 shares of common stock - Stock Titan
Tiziana Life Sciences Chairman Boosts Stake to Nearly 35% in July Share Purchase - The Globe and Mail
Tiziana Life Sciences (TLSA) Executive Chairman Increases Stake - GuruFocus
Tiziana Life Sciences says executive chairman increased stake with share purchase - Proactive financial news
Tiziana Life Sciences Announces Purchase of Shares by Executive Chairman - The Manila Times
Tiziana Life Sciences (Nasdaq: TLSA) chair lifts holding to 34.93% stake - Stock Titan
Tiziana Life Sciences Ltd. - Via Ritzau
Tiziana Life Sciences (TLSA) Sees Pullback as Shares Test Key Support ZoneRetail Driven Moves - dars.gov.et
symbol__ Stock Quote Price and Forecast - CNN
Keeren Rameshchandra Shah Net Worth (2026) - GuruFocus
Tiziana Life Sciences (TLSA) Slips 2.73% as Stock Tests Key Support LevelsStock News - dars.gov.et
Tiziana Life Sciences (NASDAQ:TLSA) Rating Increased to Hold at Zacks Research - MarketBeat
Tiziana Life Sciences Ltd Stock (TLSA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Tiziana Life Sciences Ltd Stock (TLSA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Elrifi Ivor | Chief Executive Officer |
Aug 04 '26 |
Buy |
0.97 |
83,807 |
81,293 |
4,556,068 |
| Elrifi Ivor | Chief Executive Officer |
Aug 03 '26 |
Buy |
1.00 |
667,000 |
667,000 |
4,472,261 |
2.67%
0.04%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):